Drug intelligence / Profile preview

HS-10502

Development stage: Phase 1
Lead developer: Hansoh Pharmaceutical Group
Modality: Small Molecules
Administration: Oral

Overview

HS-10502 is an orally bioavailable, selective small molecule inhibitor of poly(ADP-ribose) polymerase 1 (PARP1), developed for the treatment of advanced solid tumors. By selectively binding to and inhibiting PARP1, HS-10502 blocks the repair of damaged DNA via the base excision repair pathway, leading to accumulation of DNA damage and potential cancer cell death. The drug is being investigated in phase I clinical trials for various advanced cancers, including recurrent ovarian cancer, HER2-negative advanced breast cancer (including triple-negative breast cancer), advanced prostate carcinoma, and advanced gastric carcinoma. It is being developed by Jiangsu Hansoh Pharmaceutical[1][3][4][5][7].

Targets

PARP1 (Poly (adp-ribose) polymerase 1)

Beyond the preview

Go deeper on HS-10502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HS-10502.

Explore the full profile